Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Jaguar Health Inc (NQ: JAGX ) 1.270 +0.090 (+7.63%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Jaguar Health Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Jaguar Health Reports Second Quarter 2024 Financial Results August 13, 2024 Via ACCESSWIRE REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients August 12, 2024 Via ACCESSWIRE Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful August 05, 2024 Via ACCESSWIRE Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy August 02, 2024 Via ACCESSWIRE Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting August 01, 2024 Via ACCESSWIRE Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) July 31, 2024 Via ACCESSWIRE Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement June 26, 2024 Via ACCESSWIRE Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders June 21, 2024 Via ACCESSWIRE Jaguar Health, Inc. Announces Reverse Stock Split May 17, 2024 Via ACCESSWIRE Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer July 23, 2024 Via ACCESSWIRE Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning July 18, 2024 Via ACCESSWIRE Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs) July 08, 2024 Via ACCESSWIRE Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024 June 12, 2024 Via ACCESSWIRE Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 Via ACCESSWIRE Nasdaq Stocks Soaring to the Top with Strategic Splits: NVDA, INBS, JAGX, SINT, GWAV June 04, 2024 Via AB Newswire Exposures Product Safety Jaguar Health Reports First Quarter 2024 Financial Results May 14, 2024 Via ACCESSWIRE REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates May 13, 2024 Via ACCESSWIRE Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates May 08, 2024 Via ACCESSWIRE Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia May 29, 2024 Via ACCESSWIRE Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea May 28, 2024 Via ACCESSWIRE Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product May 23, 2024 Via ACCESSWIRE Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe May 09, 2024 Via ACCESSWIRE Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID) April 29, 2024 Via ACCESSWIRE Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders April 09, 2024 Via ACCESSWIRE Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement April 08, 2024 Via ACCESSWIRE Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International April 02, 2024 Via ACCESSWIRE Jaguar Health Reports 2023 Financial Results April 01, 2024 Via ACCESSWIRE Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care April 22, 2024 Via ACCESSWIRE Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care April 18, 2024 Via ACCESSWIRE Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates March 27, 2024 Via ACCESSWIRE < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.